BSD Medical Corporation (NASDAQ:BSDM) (the "Company" or "BSD") announced today that the Cancer Treatment Centers of America (CTCA), located in Tulsa, Oklahoma, has purchased a BSD-2000 Hyperthermia System (BSD-2000). CTCA in Tulsa is a state-of-the-art hospital that is totally focused on treating cancer patients and provides the most advanced therapeutic resources in cancer treatment (http://www.cancercenter.com/southwestern-hospital.cfm). CTCA is a network of hospitals and one of the premier providers of cancer care in the world. The CTCA hospitals were recently recognized by the Commission on Cancer of the American College of Surgeons as "offering the very best in cancer care." This advanced cancer treatment facility was designed in cooperation with cancer patients and their care givers.
“offering the very best in cancer care.”
"CTCA already offers hyperthermia treatment with the BSD-500 Hyperthermia System to our patients, and we are excited to add the BSD-2000 to our hyperthermia program. CTCA is always searching for powerful therapies to offer our patients, and we look forward to participating in the clinical evaluation of this innovative technology," said Oneita Taylor, MD, Radiation Oncologist at CTCA.
CTCA physicians specialize in treating many types of cancer, including complex and advanced stage cases. The cancer experts employed by CTCA work as a team across multiple disciplines to provide an individualized cancer treatment plan designed to treat the whole person. CTCA is committed to revolutionizing cancer care by providing the most advanced and effective cancer treatments and supportive therapies available in order to treat the cancer and improve the patient's treatment experience and quality of life.
The BSD-2000 - developed and patented exclusively by BSD - delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the 3-dimensional shape, size, and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 is restricted to investigational use in the US, and the Company is currently conducting a clinical study to evaluate the safety and efficacy of hyperthermia using the BSD-2000 combined with radiotherapy for the treatment of patients suffering from locally advanced, persistent, or recurrent deep tumors of the pelvis: i.e., cervical, prostate, rectal, and bladder. BSD has also applied for a Humanitarian Device Exemption (HDE) approval for its BSD-2000 Hyperthermia System and this submission is still under review by the FDA.
New AI model offers hope for detecting brain cancer spread without surgery